Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Small Cell Lung Carcinoma 8Lung Neoplasms 4Sarcoma, Ewing 2Sarcoma 2SCLC, Extensive Stage 1Recurrence 1Platinum-Resistant Lung Small Cell Carcinoma 1Ovarian Neoplasms 1Neutropenia 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Gastrointestinal Malignancies 1Endometrial Neoplasms 1Desmoplastic Small Round Cell Tumor 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 37Gemcitabine 29Nivolumab 20Cisplatin 19atezolizumab 15avelumab 14Docetaxel 13enfortumab vedotin 10Carboplatin 10durvalumab 9Magnetic Resonance Spectroscopy 9Ipilimumab 8Paclitaxel 7Pemetrexed 6toripalimab 5cabozantinib 5Fluorodeoxyglucose F18 5sacituzumab govitecan 4cabazitaxel 4Taxes 4vinflunine 3tremelimumab 3pemigatinib 3X-Rays 3Standard of Care 3Specimen Handling 3Radiotherapy 3Mitomycin 3Immunotherapy 3Immunoglobulin G 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Transitional Cell × PM 01183 × Clear all
NCT05574504 2024-08-01

Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

AdventHealth

Phase 2 Withdrawn
Genitourinary

Carcinoma, Transitional Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡